A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
- Conditions
- Interventions
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 563
- Registration Number
- NCT03115476
- Locations
- 🇺🇸
DermAssociates, PC, Rockville, Maryland, United States
🇺🇸Southern California Dermatology, Inc., Santa Ana, California, United States
🇬🇧Investigational Site, Redhill, Surrey, United Kingdom
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 420
- Registration Number
- NCT03099031
- Locations
- 🇫🇷
George Pompidou European Hospital, Paris, France
Vasoconstriction Trial With LEO 90100 Aerosol Foam
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT02973776
- Locations
- 🇫🇷
CPCAD, Nice, Cedex, France
PSOREAL - Managing PSOriasis in the REAL World
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1214
- Registration Number
- NCT02935582
- Locations
- 🇸🇪
Psoriasis association in Stockholm region, Stockholm, Sweden
🇨🇦Dr. Chih-Ho Hong Medical Inc., Surrey, British Columbia, Canada
🇬🇧Layton Medical Centre, Blackpool, Lancashire, United Kingdom
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 722
- Registration Number
- NCT02899962
- Locations
- 🇺🇸
Arlington Dermatology, Arlington Heights, Illinois, United States
🇨🇦Brunwick Dermatology Center, Fredericton, New Brunswick, Canada
🇬🇧Albany House Medical Centre, Wellingborough, Northamptonshire, United Kingdom
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT02888236
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Dept. of Dermatology, Berlin, Germany
Efficacy and Tolerability of Enstilar® in Daily Practice
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 410
- Registration Number
- NCT02881346
- Locations
- 🇩🇪
Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein, Kiel, Germany
Real-life Evaluation of the Daivobet® Gel Applicator
- Conditions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1560
- Registration Number
- NCT02856542
- Locations
- 🇫🇷
Cabinet de Dermatologie, Dr. Mathilde Kemula, Charenton le Pont, France
A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT02753218
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds, United Kingdom
Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 69
- Registration Number
- NCT02695940
- Locations
- 🇩🇪
Johannes Niesmann, Bochum, Germany